An evaluation of clinical pharmacist contributions in paediatrics

McArtney, R. J.; McArtney, R. G.; Postle, J. A.; Williams, R.
April 2011
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1
Academic Journal
Objective To collect clinical pharmacists interventions to profile pharmacy services, evaluate training needs and support business planning for the service; to classify these interventions by severity and stage of medication use process; and to demonstrate the financial value of pharmacists interventions in Paediatrics. Methods This study used data collected by clinical pharmacists across Wales who recorded interventions at ward level on paper or using a PDA. Data is collected on 1 day each month on a rolling basis allowing data to be evaluated for a virtual week. Interventions are classified according to four main processes (prescribing, administration, supply and advice/monitoring). Guidance is provided to help classify severity and likelihood of recurrence. Interventions are recorded as an actual event or a 'near-miss⇔(tm). The All Wales Intervention Database (AWID) is used to record this information and provide data analysis. Data for C&V UHB is entered by a single individual who uses Peer Review to reclassify incidents where necessary. Results Over a virtual 1-week period in 2010, 1539 interventions were made by pharmacists in C&VUHB. There were 128 interventions in Paediatrics collected by eight pharmacists over 5 days. Severity classification of these interventions were: Catastrophic (0), Major (4), Moderate (36), Minor (30), Information only (46). Examples of major interventions include a four times overdose of intravenous paracetamol and use of expired tacrolimus suspension brought in from home. Many interventions relate to incorrect doses for weight, age, route and renal function. Incomplete medicines reconciliation was common as were uncompleted allergy boxes. It is possible to demonstrate potential cost savings of these clinical contributions by using a model (commissioned by NICE) that places a financial value on the intervention according to severity. For Paediatrics these costs were £7 690 over a virtual 1-week period. Conclusion The role of the clinical pharmacist in paediatric care was examined in a systematic literature review which concluded that pharmacist reviewing of medication charts is important in identification of medication errors.1 This study demonstrates the types of interventions pharmacists make which can be classified according to multiple factors such as specialty, severity and stage of care. Although there is a lack of published information on the economic value of clinical pharmacist contributions to patient care, the ScHARR principles allow an assessment of the financial impact of these interventions to be made.2 Intervention monitoring is especially helpful to demonstrate the key role undertaken by Pharmacists in Paediatrics. AWID is supported by the Heads of Pharmacy in the Health Boards across Wales. Data collection is repeated on an annual basis and the results are widely used to support and target service delivery.


Related Articles

  • A descriptive retrospective study into pharmacy led paediatric commissioning services when processing individual funding requests for PCTs. Ubhi, H. K.; Terry, D. R. P. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1 

    Objective To quantify the success of a Pharmacist led paediatric commissioning service in securing individual funding requests (IFR) to Primary Care Trusts (PCTs). Methods Descriptive, retrospective study over a 4 month period by review of IFR sent to PCTs. The IFRs were completed by the lead...

  • Development of a single paediatric infliximab administration guideline. Kasuji, S.; Wood, M.; Lilley, R.; Collins, S. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1 

    Objective Three separate infliximab prescribing and administration guidelines were being used within the paediatric departments at LTHT. Over a 6 month period this caused selection errors which resulted in a number of administration rate errors. The aim of this project was to develop a single...

  • PICU pharmacist interventions: what can they tell us? Isaac, R.; Gerrard, A. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1 

    Objective The Pharmacy Paediatric Intensive Care (PICU) team record interventions that affect a patient's episode on PICU. These interventions are not always reported via the hospital's incident reporting route. The aim of this report is to highlight information that may benefit or influence a...

  • Clinical trials of medicines in children. Choonara, Imti // BMJ: British Medical Journal (International Edition);11/04/2000, Vol. 321 Issue 7269, p1093 

    Editorial. Focuses on the lack of scientific data related to the use of medicines in children. Reluctance of the pharmaceutical industry to conduct clinical trials of medicines in children; Efforts of the United States Food and Drug Administration (FDA) to encourage such studies; Practical...

  • Assessing Prescription Writing Skills of House Officers in Dental Teaching Hospitals of Karachi, Pakistan. Wali, Aisha; Ali, Anwar; Siddiqui, Talha Mufeed; Jafri, Hamza // World Journal of Dentistry;Oct-Dec2012, Vol. 3 Issue 4, p294 

    Introduction: A prescription is 'a written order, which includes detailed instructions of what medicine should be given to whom, in what formulation and dose, by what route, when, how frequently, and for how long'. Aim: To determine competency and knowledge gained during undergraduate dental...

  • Success Using Tacrolimus in Patients with Proliferative and Membranous Lupus Nephritis and Refractory Proteinuria. Gordon, Sarah; Denunzio, Troy; Uy, Alice // Hawaii Journal of Medicine & Public Health;Sep2013 Supplement 4, Vol. 72 Issue 9, p18 

    Standard treatment for class III, IV, and V lupus nephritis (LN) is a combination of oral corticosteroids and mycophenolate mofetil (MMF). There is an estimated failure rate of 16%. Several small studies have looked at the use of tacrolimus in class III, IV, and V LN, both as induction treatment...

  • Ciclosporin to tacrolimus switch improves QOL.  // Reactions Weekly;8/26/2006, Issue 1116, p3 

    The article reports on a study which found that switching from ciclosporin to tacrolimus due to ciclosporin-related adverse effects improves disease-specific quality of life (QOL) in renal transplant patients but leaves global QOL unchanged.

  • Thiazides may prevent tacrolimus-induced hypertension.  // Reactions Weekly;10/29/2011, Issue 1375, p4 

    The article discusses research on the efficacy of thiazides in preventing tacrolimus-induced hypertension, by E. J. Hoorn and colleagues, published in "Nature Medicine."

  • Tacrolimus.  // Reactions Weekly;Apr2015, Vol. 1545 Issue 1, p230 

    The article discusses a study published in the February 2014 issue of "Pediatric Transplantation" that presented a case report of tacrolimus-related seizure after pediatric liver transplantation.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics